Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    EUR1m

    Last close

    EUR0.10

    ▲ 0.06 (150.00%)

    Actinogen Medical

    MCap

    AUD48m

    Last close

    AUD0.03

    ▲ 0.01 (50.00%)

    DFR Gold

    MCap

    CAD13m

    Last close

    CAD0.10

    ▲ 0.03 (42.86%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

InMed Pharmaceuticals – Introducing the BayMedica Team

InMed Pharmaceuticals – Introducing the BayMedica Team

Associated equity: InMed Pharmaceuticals

Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

View this company

InMed Pharmaceuticals — 14 videos in collection

InMed Pharmaceuticals is a global leader in the manufacture and development of rare cannabinoids. Together with its recently acquired subsidiary, BayMedica, it has unparalleled cannabinoid manufacturing capabilities to serve a wide spectrum of consumer markets, including pharmaceutical and health and wellness.

In this video series, we’ll be introducing the BayMedica team, discussing the team members’ impressive careers and experience in the industry and what excites them about the InMed/BayMedica acquisition. Today’s video highlights Charles Marlowe, VP of Chemistry.

< Previous
Next >

You may also be interested in these:

Healthcare

InMed Pharmaceuticals: Edison Open House Healthcare 2022

Healthcare

InMed Pharmaceuticals – Introducing the BayMedica team

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free